- ECHA
- Leġiżlazzjoni
- REACH
- Valutazzjoni
- Progress fil-valutazzjoni
- Progress in evaluation 2022
- Follow-up evaluation 2022
Progress in evaluation in 2022
Progress in evaluation in 2022
L-informazzjoni ġdida riċevuta b’riżultat ta’ deċiżjoni tal-ECHA tiġi skrinjata biex jiġi vverifikat jekk it-talbiet ġewx issodisfati u jekk kienx hemm kjarifika rigward il-periklu jew it-tħassib, u biex jiġi identifikat kwalunkwe każ fejn jistgħu jkunu meħtieġa azzjonijiet regolatorji ulterjuri.
Segwitu għall-valutazzjoni tad-dossier
Fl-2022, 438 sustanza laħqu l-istadju tas-segwitu għall-valutazzjoni tad-dossier. Il-proċess ġie konkluż għal 249 sustanza.
Għal 152 sustanza, ir-reġistranti ssottomettew l-informazzjoni meħtieġa sal-iskadenza mogħtija. Ġew identifikati 37 sustanza bħala sustanzi li jeħtieġu klassifikazzjoni u tikkettar armonizzati. Waħda kienet teħtieġ valutazzjoni ulterjuri relatata mal-proprjetajiet persistenti, bijoakkumulattivi u tossiċi tagħha. Erba’ sustanzi tqiesu bħala kandidati għall-valutazzjoni tas-sustanzi (SEv).
Ammont ta’ 151 valutazzjoni ta’ segwitu li koprew 146 sustanza ġew riferuti lill-awtoritajiet nazzjonali tal-infurzar minħabba li r-reġistranti ma pprovdewx l-informazzjoni mitluba fil-ħin.
Wara l-azzjonijiet ta’ infurzar, ir-reġistranti ssottomettew l-informazzjoni meħtieġa fi 82 każ. Il-valutazzjonijiet imwettqa wara li l-każ ġie riferut lill-awtoritajiet nazzjonali tal-infurzar ma jiġux miżjuda fit-tabella ta’ hawn taħt bħala valutazzjoni separata minħabba li jitqiesu bħala parti mill-valutazzjoni oriġinali.
Number and outcome on substances subject to follow ups to dossier evaluation 2023
Decision type | Outcome | ||||
---|---|---|---|---|---|
Substances compliant with decision by the deadline | Substances compliant with decision after involving national enforcement authorities1 | Substances non-compliant with decision, assessments still open2 | Substances non-compliant with the decision, a new decision issued3 | Substances proposed as candidates for further regulatory process | |
Testing proposal decisions | 67 | 37 | 92 | 3 | 20 CLH, 1 SEv |
Compliance check decisions | 85 | 45 | 174 | 12 | 17 CLH, 3 SEv, 1 PBT |
Total | 152 | 82 | 266 | 15 | 37 CLH, 4 SEv, 1 PBT |
CLH: harmonised classification and labelling
1No or inadequate information was provided by the deadline. ECHA invited Member State competent authorities to consider enforcement actions against the registrant. This led to a dossier update with sufficient information.
2 No or inadequate information was provided by the deadline. ECHA invited Member State competent authorities to consider enforcement actions against the registrant. The requested information has not yet been provided.
3 Information has been provided, but the information requirement was not met.
Segwitu għall-valutazzjoni tas-sustanzi
Fl-2022, ġew ivvalutati 23 sustanza. Għal erba’ sustanzi, l-awtorità kompetenti tal-Istat Membru responsabbli mill-valutazzjoni talbet aktar informazzjoni minħabba li l-informazzjoni sottomessa ma kkjarifikatx it-tħassib oriġinali, jew qajmet aktar tħassib.
Għad-19-il sustanza li kien jifdal, l-awtoritajiet sabu li l-informazzjoni disponibbli kienet suffiċjenti biex jiġi kkjarifikat it-tħassib u setgħu jikkonkludu jekk kienx hemm ħtieġa ta’ azzjoni regolatorja ulterjuri.
Konklużjonijiet
L-awtorità kompetenti tal-Istat Membru responsabbli mill-valutazzjoni tista’ tipproponi waħda jew aktar mill-azzjonijiet regolatorji li ġejjin biex tindirizza t-tħassib:
- klassifikazzjoni u tikkettar armonizzati għal sustanzi li huma karċinoġeniċi, mutaġeniċi jew tossiċi għar-riproduzzjoni, sensitizzaturi respiratorji, jew li joħolqu tħassib ieħor, eż. huma perikolużi għall-ambjent akkwatiku;
- identifikazzjoni bħala sustanza ta’ tħassib serju ħafna (SVHC);
- restrizzjoni tas-sustanza; jew
- azzjonijiet barra l-kamp ta’ applikazzjoni ta’ REACH bħal-limiti ta’ esponiment professjonali fl-UE kollha, miżuri nazzjonali jew azzjonijiet industrijali volontarji.
Summary of concluded substance evaluations where further regulatory actions were proposed
Suspected concern | Concluded regulatory follow-up action at EU level | Concluded substances by EC/List number | Evaluating MSCA |
---|---|---|---|
Carcinogenicity | Harmonised classification and labelling | 204-077-3 | FR |
225-935-3 | DE | ||
Identification as an SVHC | 204-077-3 | FR | |
Mutagenicity | Harmonised classification and labelling | 218-645-3 | DK |
Reproductive toxicity | Harmonised classification and labelling | 229-962-1 | DE |
273-227-8 | DE | ||
To be confirmed* | 201-126-0 | FR | |
200-843-6 | FR | ||
PBT/vPvB** | Identification as an SVHC | 203-497-4 | NO |
205-491-7 | NO | ||
205-492-2 | NO | ||
473-390-7 | BE | ||
Restriction | 203-497-4 | NO | |
205-491-7 | NO | ||
205-492-2 | NO | ||
To be confirmed* | 203-497-4 | NO | |
205-491-7 | NO | ||
205-492-2 | NO | ||
473-390-7 | BE | ||
Endocrine disruption | To be confirmed* | 201-126-0 | FR |
Sensitisation (skin and/or respiratory) | Harmonised classification and labelling | 201-983-0 | DE |
204-077-3 | FR | ||
218-645-3 | DK | ||
273-227-8 | DE | ||
Identification as an SVHC | 204-077-3 | FR | |
Other concern | Harmonised classification and labelling | 201-052-9 | FR |
201-983-0 | DE | ||
204-077-3 | FR | ||
211-463-5 | DE | ||
215-160-9 | FR | ||
229-962-1 | DE | ||
246-677-8 | IT | ||
Restriction | 468-710-7 | DE | |
Other EU-wide regulatory risk management measures | 215-160-9 | FR | |
468-710-7 | DE | ||
To be confirmed* | 201-052-9 | FR | |
211-463-5 | DE | ||
215-160-9 | FR | ||
216-653-1 | FR |
* A need for further regulatory actions at EU level was identified but the risk management options analysis was not yet finalised. The evaluating MSCA will prepare a separate risk management option analysis to clarify the appropriate follow-up regulatory actions.
** PBT: persistent, bioaccumulative and toxic; vPvB: very persistent and very bioaccumulative.